The Cancer Screening Research Network (CSRN) Communications and Coordinating Center (CCC) is led by three senior principal investigators at Fred Hutch Cancer Center who bring complementary training and expertise encompassing all scientific and functional aspects critical to the CSRN mission. The CCC will develop study protocols and train and monitor the nine U.S. organizations that recruit participants to studies. Other investigators will provide additional expertise in recruitment and retention of minority and underserved populations, cancer diagnostic pathways and clinical practice more generally.
CCC Leadership
Garnet Anderson, PhD
Ruth Etzioni, PhD
Scott Ramsey, MD, PhD
The CCC is Organized Into Four Units
CCC Co-Investigators
Charles Drescher, MD
Rachel Issaka, MD, MAS
Vida Henderson, PhD, PharmD
Paul Lampe, PhD
Christoph Lee, MD, MS, MBA
Matthew Triplette MD, MPH
Frequently Asked Questions
CSRN is the first large scale network to focus on cancer screening. It will be led by clinicians who perform cancer screening as part of their routine practice. CSRN will engage providers who work with large and diverse populations receiving routine healthcare in a variety of healthcare settings.
Yes. The CSRN plans to investigate a variety of emerging technologies for cancer screening. These may include screening methods that involve imaging, biomarkers, procedures, combinations of the above, or tests that have not yet been invented.
The first effort for CSRN is a pilot study called the Vanguard study which will inform the design of future large trials to evaluate MCD assays.
Because CSRN is funded through a cooperative agreement, NCI plays a role in all aspects of the CSRN. Read more on the NCI CSRN site.
Yes, CSRN will engage large and diverse populations receiving routine healthcare in a variety of healthcare settings. The funded ACCESS Hubs have detailed recruitment plans that include engaging participants from Federally Qualified Health Centers, rural populations, tribal nations and racially and socioeconomically diverse populations. The goal is to ensure that the results of the CSRN trials apply to diverse populations.